EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Treatment of High-Risk Neuroblastoma with Dinutuximab and Chemotherapy Administered in all Cycles of Induction

Margaret Cupit-Link iD, Sara M Federico

Cancers · 18.09.2023 · 15 (18) · 4609

DOI: 10.3390/cancers15184609 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancers, online erschienen am 18.09.2023. Verfasst von Margaret Cupit-Link und 1 weiteren Autor:innen. Beteiligte Einrichtung: St. Jude Children's Research Hospital, Memphis, TN 38105, USA. Die Arbeit wurde bisher 14-mal zitiert (Crossref) und nennt 29 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NCI NIH HHS, Cancer Center.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Administration of chemoimmunotherapy using concurrent chemotherapy and an anti-GD2 monoclonal antibody (mAb), dinutuximab (DIN), demonstrated efficacy for the treatment of relapsed and refractory neuroblastoma. Chemoimmunotherapy, using a humanized anti-GD2 mAb, demonstrated a signal of activity in a phase 2 study for the treatment of patients with newly diagnosed high-risk neuroblastoma (HRNBL). In this single-institution retrospective study, patients with HRNBL received an Induction chemotherapy regimen plus DIN in all Induction cycles. Toxicity and response data were abstracted from the electronic medical record. Toxicities were graded by CTCAE v.5.0. The end of Induction (EOI) objective response rate was determined using the Revised International Neuroblastoma Response Criteria. Twenty-seven patients with HRNBL (23 newly diagnosed, 16 females, median age 3.9 years) started Induction chemoimmunotherapy from 27 January 2017 to 28 December 2022. All patients received DIN with all cycles of Induction therapy, and all but one patient completed Induction therapy. The most common non-hematologic grade ≥ 3 toxicities included fever (44%), hypoxemia (20%), and hypoalbuminemia (11%). End of Induction responses included eighteen with a complete response (CR), seven with a partial response (PR), one with progressive disease (PD), and zero with a minor response or stable disease. Twenty-six of twenty-seven patients (96%) completed all Induction cycles and were evaluable for a response. The EOI response of PR or better in the evaluable cohort was 96%. Dinutuximab was well tolerated with all Induction cycles, demonstrated an encouraging EOI response rate, and should be evaluated in a randomized study.

Schlagwörter

Stichwörter der Autor:innen

Inductionchemoimmunotherapydinutuximabhigh-riskneuroblastoma

Autor:innen und Institutionen

  • St. Jude Children's Research Hospital, Memphis, TN 38105, USA.

ORCID-Profile: Margaret Cupit-Link

Förderung

  • NCI NIH HHS
  • Cancer Center

Zitieren

APA

Cupit-Link, M., & Federico, S. M. (2023). Treatment of High-Risk Neuroblastoma with Dinutuximab and Chemotherapy Administered in all Cycles of Induction. Cancers, 15(18), 4609. https://doi.org/10.3390/cancers15184609

Vancouver

Cupit-Link M, Federico SM. Treatment of High-Risk Neuroblastoma with Dinutuximab and Chemotherapy Administered in all Cycles of Induction. Cancers. 2023;15(18):4609. doi:10.3390/cancers15184609

BibTeX
@article{CupitLink2023,
  author = {Cupit-Link, Margaret and Federico, Sara M},
  title = {Treatment of High-Risk Neuroblastoma with Dinutuximab and Chemotherapy Administered in all Cycles of Induction},
  journal = {Cancers},
  year = {2023},
  volume = {15},
  number = {18},
  pages = {4609},
  doi = {10.3390/cancers15184609}
}
Kostenlos starten →